GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Northwest Biotherapeutics Inc (LTS:0K95) » Definitions » Short Percentage of Float

Northwest Biotherapeutics (LTS:0K95) Short Percentage of Float


View and export this data going back to 2018. Start your Free Trial

What is Northwest Biotherapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Northwest Biotherapeutics's Short Percentage of Float

For the Biotechnology subindustry, Northwest Biotherapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Northwest Biotherapeutics's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Northwest Biotherapeutics's Short Percentage of Float falls into.


Northwest Biotherapeutics (LTS:0K95) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Northwest Biotherapeutics Inc (LTS:0K95) » Definitions » Short Percentage of Float
Comparable Companies
CABA YMAB ALLO ALT HRTX OABI TRDA LXEO CDMO ADPT OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
NWBO:USA NBYB:Germany
Address
4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814
Website
https://www.nwbio.com
Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.

Northwest Biotherapeutics (LTS:0K95) Headlines

No Headlines